¹ Carbone PP et al. Cancer Res 1971; 31:1860.

² Harris NL, Jaffe ES, et al. Word Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tisúes: Report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835

³ Solal-celigny P, Roy P et al. Follicullar lymphoma international prognostic index. Blood 2004; 104: 1258.

⁴ A predictive model for aggressive non-Hodgkin´s lymphoma. The International Malignant Lymphoma Prognostic factors project. N Engl J Med 1993; 329: 987.

⁵ Horning SJ, Rosemberg SA. The natural history of initially untreated low-grade non-Hodgkin´s lymphomas. N Engl J Med 1984; 311:1471.

⁶ Mac Manus, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282.

⁷ Wilder RB, Jones D, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51: 1219.

⁸ Ardeshna KM, Smith P, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516.

⁹ Press OW, Unger JM, et al. A phase 2 trail of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003; 102: 1606.

¹⁰ Klasa RJ, Meyer RM, et al. Randomized phase III study of fludarabine phosphate non-Hodgkin´s lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol 2002; 20:4649.

¹¹ Hiddemann W, Kneba M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725.

¹² Van Oers MH, Klasa R, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295.

¹³ Welgert O, Illidge T et al. Recommendations for the use of Yttrium-90ibritumomab tiuxetan in malignant lymphoma. Cancer 2006; 107: 686.

¹⁴ Press OW, Unger JM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin`s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S 9911. J Clin Oncol 2006; 24:4143.

¹⁵ Miller T, Dahlberg S, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-hodgkin´s lymphoma. N Engl J Med 1998; 339: 21.

¹⁶ Horning SJ, Weller E, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive Non-hodgkin´s lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 2004; 22:3032.

¹⁷ Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study the Groupe d´Etude des lymphomas de l´Adulte. J Clin Oncol 2007; 25 :787.

¹⁸ Pfreundschuh M, Trumper L, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mabthera International Trial (MinT) Group . Lancet oncol 2006; 7:379.

¹⁹ Fisher R, Gaynor E, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-hodgkin´s lymphoma. N Engl J Med 1993; 328:1002.

²⁰ Coiffier B, Lepage E et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235.

ⁱ Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease Discovery. Blood 2008; 112: 4384-99.

ⁱⁱ Arcaini L, Merli M, Passamonti F, Rizzi S, Ferretti V, et al. Validation of follicular lymphoma International prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol 2010, 149 (3): 455-7

ⁱⁱⁱ Federico M, Bellei M, Marcheselli L, Luminari S, et al. Follicular lymphoma International prognostic index 2: a new prognostic index for follicular lymphoma developed by the International follicular lymphoma prognostic factor Project. J Clin Oncol 2009; 27(27): 4555-62.

^iv Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M; Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474-9

<< volver